Several other ICIs have been studied for use in cSCC, including nivolumab (anti-PD-1), ipilimumab (anti-CTLA04), avelumab (anti-PD-L1), and relatimab (LAG-3). Here, PDCD1 is linked to skin squamous cell carcinoma.